Aileron Therapeutics files for a $69M IPO as new offerings heat up
Aileron Therapeutics has set out to raise $69 million in the latest biotech IPO to hit the street.
Their lead drug — ALRN-6924 — is focused …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
